Bronchodilators: Current and future

Clinics in Chest Medicine

Volumn 35, Issue 1, 2014, Pages 191-201

  Cazzola, Mario ^a   Matera, Maria Gabriella ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

2 Agonists; Antimuscarinic agents; Choice of bronchodilators; Chronic obstructive pulmonary disease; Emerging bronchodilators; Methylxanthines

Indexed keywords

ANTIMUSCARINIC AGENTS; CHOICE OF BRONCHODILATORS; CHRONIC OBSTRUCTIVE PULMONARY DISEASE; EMERGING BRONCHODILATORS; METHYLXANTHINES; Β(2)-AGONISTS;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; BRONCHODILATOR AGENTS; DRUG THERAPY, COMBINATION; HUMANS; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; THEOPHYLLINE;

EID: 84893722023     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2013.10.005     Document Type: Review

References (84)

1. Cazzola M., Page C.P., Calzetta L., et al. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev 2012, 64:450-504.
2. Thomas M., Decramer M., O'Donnell D.E. No room to breathe: the importance of lung hyperinflation in COPD. Prim Care Respir J 2013, 22:101-111.
3. O'Donnell D.E., Banzett R.B., Carrieri-Kohlman V., et al. Pathophysiology of dyspnea in chronic obstructive pulmonary disease: a roundtable. Proc Am Thorac Soc 2007, 4:145-168.
4. National Clinical Guideline Centre Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care 2010, National Clinical Guideline Centre, London, Available at:, Accessed March 20, 2013. http://guidance.nice.org.uk/CG101/Guidance/pdf/English.
5. Qaseem A., Wilt T.J., Weinberger S.E., et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011, 155:179-191.
6. Vestbo J., Hurd S.S., Agustí A.G., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013, 187:347-365.
7. 2-Adrenoceptor agonists: current and future direction. Br J Pharmacol 2011, 163:4-17.
8. 2-Agonist therapy in lung disease. Am J Respir Crit Care Med 2013, 187:690-696.
9. 2-agonists in the treatment of stable chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2013, 8:53-64.
10. Wang J., Nie B., Xiong W., et al. Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis. JClin Pharm Ther 2012, 37:204-211.
11. Suissa S., Ernst P., Vandemheen K.L., et al. Methodological issues in therapeutic trials of COPD. Eur Respir J 2008, 31:927-933.
12. Rogers D.F. Mucociliary dysfunction in COPD: effect of current pharmacotherapeutic options. Pulm Pharmacol Ther 2005, 18:1-8.
13. 2-adrenergic agents: is it a real clinical problem?. Pulm Pharmacol Ther 2012, 25:4-10.
14. Cazzola M., Rogliani P., Ruggeri P., et al. Chronic treatment with indacaterol and airway response to salbutamol in stable COPD. Respir Med 2013, 107:848-853.
15. Cazzola M., Page C., Matera M.G. Long-acting muscarinic receptor antagonists for the treatment of respiratory disease. Pulm Pharmacol Ther 2013, 26:307-317.
16. Cazzola M., Page C., Matera M.G. Aclidinium bromide for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother 2013, 14:1205-1214.
17. Buhl R., Banerji D. Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD. Int J Chron Obstruct Pulmon Dis 2012, 7:729-741.
18. Lee T.A., Pickard A.S., Au D.H., et al. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med 2008, 149:380-390.
19. Singh S., Loke Y.K., Enright P.L., et al. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ 2011, 342:d3215.
20. Ito K., Lim S., Caramori G., et al. Amolecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci U S A 2002, 99:8921-8926.
21. To Y., Ito K., Kizawa Y., et al. Targeting phosphoinositide-3-kinase-δ with theophylline reverses corticosteroids insensitivity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010, 182:897-904.
22. Lee T.A., Schumock G.T., Bartle B., et al. Mortality risk in patients receiving drug regimens with theophylline for chronic obstructive pulmonary disease. Pharmacotherapy 2009, 29:1039-1053.
23. Cazzola M., Segreti A., Rogliani P. Comparative effectiveness of drugs for chronic obstructive pulmonary disease. Drugs Today (Barc) 2012, 48:785-794.
24. van den Boom G., Rutten-van Mölken M.P., Tirimanna P.R., et al. Association between health-related quality of life and consultation for respiratory symptoms: results from the DIMCA programme. Eur Respir J 1998, 11:67-72.
25. d'Andiran G., Schindler C., Leuenberger P. The absence of dyspnoea, cough and wheezing: a reason for undiagnosed airflow obstruction?. Swiss Med Wkly 2006, 136:425-433.
26. Shin C., Lee S., Abbott R.D., et al. Respiratory symptoms and undiagnosed airflow obstruction in middle-aged adults: the Korean health and genome study. Chest 2004, 126:1234-1240.
27. Lu M., Yao W.Z., Zhong N.S., et al. Asymptomatic patients of chronic obstructive pulmonary disease in China. Chin Med J 2010, 123:1494-1499.
28. Cazzola M., Brusasco V., Centanni S., et al. Project PriMo: sharing principles and practices of bronchodilator therapy monitoring in COPD: a consensus initiative for optimizing therapeutic appropriateness among Italian specialists. Pulm Pharmacol Ther 2013, 26:218-228.
29. Ohar J.A., Donohue J.F. Mono- and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD. Semin Respir Crit Care Med 2010, 31:321-333.
30. 2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 163:1087-1092.
31. Dahl R., Greefhorst L.A., Nowak D., et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 164:778-784.
32. Singh D., Magnussen H., Kirsten A., et al. Arandomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients. Pulm Pharmacol Ther 2012, 25:248-253.
33. Donohue J.F., van Noord J.A., Bateman E.D., et al. A6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002, 122:47-55.
34. Vogelmeier C., Hederer B., Glaab T., et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. NEngl J Med 2011, 364:1093-1103.
35. 2-agonist indacaterol against established treatments in chronic obstructive pulmonary disease. Ther Adv Respir Dis 2011, 5:345-357.
36. Buhl R., Dunn L.J., Disdier C., et al. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J 2011, 38:797-803.
37. Rodrigo G.J., Neffen H. Comparison of indacaterol with tiotropium or twice-daily long-acting β-agonists for stable COPD: a systematic review. Chest 2012, 142:1104-1110.
38. Mahler D.A., Buhl R., Lawrence D., et al. Efficacy and safety of indacaterol and tiotropium in COPD patients according to dyspnoea severity. Pulm Pharmacol Ther 2013, 26:348-355.
39. Salpeter S.R. Bronchodilators in COPD: impact of β-agonists and anticholinergics on severe exacerbations and mortality. Int J Chron Obstruct Pulmon Dis 2007, 2:11-18.
40. Singh S., Loke Y.K., Furberg C.D. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008, 300:1439-1450.
41. Singh S., Loke Y.K., Enright P., et al. Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications. Thorax 2013, 68:114-116.
42. Cazzola M., Calzetta L., Matera M.G. The cardiovascular risk of tiotropium: is it real?. Expert Opin Drug Saf 2010, 9:783-792.
43. Cazzola M., Imperatore F., Salzillo A., et al. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest 1998, 114:411-415.
44. 2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease. Drugs 2005, 65:1595-1610.
45. Matera M.G., Martuscelli E., Cazzola M. Pharmacological modulation of β-adrenoceptor function in patients with coexisting chronic obstructive pulmonary disease and chronic heart failure. Pulm Pharmacol Ther 2010, 23:1-8.
46. Cazzola M., Calzetta L., Bettoncelli G., et al. Cardiovascular disease in asthma and COPD: a population-based retrospective cross-sectional study. Respir Med 2012, 106:249-256.
47. Cazzola M., Santus P., Castagna F., et al. Addition of an extra dose of salmeterol Diskus to conventional dose of salmeterol Diskus in patients with COPD. Respir Med 2002, 96:439-443.
48. Cazzola M., Segreti A., Stirpe E., et al. Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol. Respir Med 2013, 107:107-111.
49. Cazzola M., Di Perna F., Noschese P., et al. Effects of formoterol, salmeterol or oxitropium bromide on airway responses to salbutamol in COPD. Eur Respir J 1998, 11:1337-1341.
50. Cazzola M., Santus P., D'Adda A., et al. Acute effects of higher than standard doses of salbutamol and ipratropium on tiotropium-induced bronchodilation in patients with stable COPD. Pulm Pharmacol Ther 2009, 22:177-182.
51. 2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther 2010, 23:257-267.
52. van der Molen T., Cazzola M. Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim Care Respir J 2012, 21:101-108.
53. Wang J., Jin D., Zuo P., et al. Comparison of tiotropium plus formoterol to tiotropium alone in stable chronic obstructive pulmonary disease: a meta-analysis. Respirology 2011, 16:350-358.
54. Mahler D.A., D'Urzo A., Bateman E.D., et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax 2012, 67:781-788.
55. Rodrigo G.J., Plaza V., Castro-Rodríguez J.A. Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: a systematic review. Pulm Pharmacol Ther 2012, 25:40-47.
56. Boswell-Smith V., Cazzola M., Page C.P. Are phosphodiesterase 4 inhibitors just more theophylline?. JAllergy Clin Immunol 2006, 117:1237-1243.
57. Matera M.G., Page C.P., Cazzola M. Novel bronchodilators for the treatment of chronic obstructive pulmonary disease. Trends Pharmacol Sci 2011, 32:495-506.
58. Matera M.G., Calzetta L., Parascandolo V., et al. Relaxant effect of brain natriuretic peptide in nonsensitized and passively sensitized isolated human bronchi. Pulm Pharmacol Ther 2009, 22:478-482.
59. Matera M.G., Calzetta L., Passeri D., et al. Epithelium integrity is crucial for the relaxant activity of brain natriuretic peptide in human isolated bronchi. Br J Pharmacol 2011, 163:1740-1754.
60. Lagente V., Naline E., Guenon I., et al. Anitric oxide-releasing salbutamol elicits potent relaxant and anti-inflammatory activities. JPharmacol Exp Ther 2004, 310:367-375.
61. 4 receptor as a new target for bronchodilator therapy. Thorax 2011, 66:1029-1035.
62. Clark A.A., Liggett S.B., Munger S.D. Extraoral bitter taste receptors as mediators of off-target drug effects. FASEB J 2012, 26:4827-4831.
63. Robinett K.S., Deshpande D.A., Malone M.M., et al. Agonist-promoted homologous desensitization of human airway smooth muscle bitter taste receptors. Am J Respir Cell Mol Biol 2011, 45:1069-1074.
64. Cazzola M., Rogliani P., Segreti A., et al. An update on bronchodilators in Phase I and II clinical trials. Expert Opin Investig Drugs 2012, 21:1489-1501.
65. Abrahams R., Moroni-Zentgraf P., Ramsdell J., et al. Safety and efficacy of the once-daily anticholinergic BEA2180 compared with tiotropium in patients with COPD. Respir Med 2013, 107:854-862.
66. Barnes N., Bateman E., Gallagher N., et al. QVA149 once daily provides superior bronchodilation versus indacaterol, glycopyrronium, tiotropium and placebo: the SHINE study. Thorax 2012, 67:A147-A148. [abstract].
67. Vogelmeier C.F., Bateman E.D., Pallante J.M., et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med 2013, 1:51-60.
68. Wedzicha J.A., Decramer M., Ficker J., et al. Dual bronchodilation with QVA149 reduces COPD exacerbations: the SPARK study. Am J Respir Crit Care Med 2013, 187:A2428. [abstract].
69. Drollmann A., Brown M., Sechaud R., et al. Effect of once-daily QVA149 on cardiac safety in healthy volunteers. Am J Respir Crit Care Med 2013, 187:A1480. [abstract].
70. Feldman G., Walker R.R., Brooks J., et al. 28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial. Pulm Pharmacol Ther 2012, 25:465-471.
71. Celli B.R., Crater G., Kilbride S., et al. A24-week randomized, double-bind, placebo-controlled study of the efficacy and safety of once-daily umeclidinium/vilanterol 125/25 mcg in COPD. Am J Respir Crit Care Med 2013, 187:A2435. [abstract].
72. Anzueto A., Decramer M., Kaelin T., et al. The efficacy and safety of umeclidinium/vilanterol compared with tiotropium or vilanterol over 24 weeks in subjects with COPD. Am J Respir Crit Care Med 2013, 187:A4268. [abstract].
73. Kelleher D., Tombs L., Crater G., et al. Aplacebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects. Am J Respir Crit Care Med 2013, 187:A1487. [abstract].
74. Maltais F., Beck E., Webster D., et al. Four weeks once daily treatment with tiotropium+olodaterol (BI 1744) fixed dose combination compared with tiotropium in COPD patients. Eur Respir J 2010, 36:1014s. [abstract].
75. Aalbers R., Maleki-Yazdi M.R., Hamilton A., et al. Dose-finding study for tiotropium and olodaterol when administered in combination via the Respimat inhaler in patients with COPD. Eur Respir J 2012, 40:525-526s. [abstract].
76. Kessler R., Partridge M.R., Miravitlles M., et al. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J 2011, 37:264-272.
77. Cazzola M., Rogliani P., Matera M.G. Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother 2013, 14:775-781.
78. Reisner C., Gotfried M., Denenberg M.B., et al. Low doses of pearl therapeutics' LAMA/LABA combination MDI (GFF MDI, PT003) provide superior bronchodilation compared to components and to open-label Spiriva Handihaler in a randomized, double-blind, placebo-controlled phase IIb study in patients with COPD. Am J Respir Crit Care Med 2013, 187:A2434. [abstract].
79. 2 agonist (MABA) molecules for the treatment of COPD. Prog Med Chem 2012, 51:71-95.
80. Wielders P.L., Ludwig-Sengpiel A., Locantore N., et al. Anew class of bronchodilator improves lung function in COPD: a trial with GSK961081. Eur Respir J 2013, 42:972-981.
81. Bateman E.D., Kornmann O., Ambery C., et al. Pharmacodynamics of GSK961081, a bi-functional molecule, in patients with COPD. Pulm Pharmacol Ther 2013, 26:581-587.
82. Bjerg A., Lundbäck B., Lötvall J. The future of combining inhaled drugs for COPD. Curr Opin Pharmacol 2012, 12:252-255.
83. Salama R.O., Young P.M., Rogueda P., et al. Advances in drug delivery: is triple therapy the future for the treatment of chronic obstructive pulmonary disease?. Expert Opin Pharmacother 2011, 12:1913-1932.
84. Norman P. Novel dihydroquinoline-based MABAs; clues to the identity of LAS-190792: evaluation of WO20111411802. Expert Opin Ther Pat 2012, 22:185-192.